Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Axsome Therapeutics (AXSM) EBIT Margin: 2022-2025

Historic EBIT Margin for Axsome Therapeutics (AXSM) over the last 3 years, with Sep 2025 value amounting to -26.97%.

  • Axsome Therapeutics' EBIT Margin rose 3281.00% to -26.97% in Q3 2025 from the same period last year, while for Sep 2025 it was -37.85%, marking a year-over-year increase of 5263.00%. This contributed to the annual value of -72.74% for FY2024, which is 1293.00% up from last year.
  • Per Axsome Therapeutics' latest filing, its EBIT Margin stood at -26.97% for Q3 2025, which was down 10.20% from -24.47% recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' EBIT Margin peaked at -6.74% during Q1 2023, and registered a low of -251.76% during Q3 2022.
  • Over the past 3 years, Axsome Therapeutics' median EBIT Margin value was -61.14% (recorded in 2024), while the average stood at -71.77%.
  • Its EBIT Margin has fluctuated over the past 5 years, first soared by 14,428bps in 2023, then tumbled by 8,296bps in 2024.
  • Quarterly analysis of 4 years shows Axsome Therapeutics' EBIT Margin stood at -245.86% in 2022, then soared by 10,847bps to -137.39% in 2023, then spiked by 7,625bps to -61.14% in 2024, then skyrocketed by 3,281bps to -26.97% in 2025.
  • Its EBIT Margin stands at -26.97% for Q3 2025, versus -24.47% for Q2 2025 and -46.91% for Q1 2025.